Back to all studies
TerminatedNCT05643170

Effectiveness of Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in schizophrenia

This study was terminated in the United States. It is testing Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT05643170. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

Check the official registry

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 5 sites
  • Advanced Discovery Research, LLC
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Seven Counties Services, Inc.
    Louisville, Kentucky
    Site status: Not listed — confirm with the team
  • Mid Ohio Behavioral Health
    Columbus, Ohio
    Site status: Not listed — confirm with the team
  • OnSite Clinical Solutions, LLC
    Rock Hill, South Carolina
    Site status: Not listed — confirm with the team
  • Integrated Clinical Research
    St. George, Utah
    Site status: Not listed — confirm with the team
In plain English

Key information made simple

What is this study testing?

This study is testing whether Xanomeline and Trospium Chloride Capsules may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Xanomeline and Trospium Chloride Capsules, attend study visits with the research team. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: November 8, 2022
Recruitment status
Terminated
Enrollment listed in the registry
4
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05643170
Official title
A Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT05643170. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Xanomeline and Trospium Chloride Capsules. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me